PREFER

Patient Preferences in benefit risk assessments during the drug life cycle
PREFER

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 5
Grant agreement number
115966

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
6 000 000
EFPIA in kind
6 000 000
Other
1
Total Cost
12 000 001

Summary

Patient perspective is important in all medical research and particularly in drug development. The PREFER project aims to assess when and how patient preferences on benefits and risks should be incorporated into decisions on medicinal products. While industry, regulatory authorities, health technology assessment bodies, reimbursement agencies and patient organisations all agree that patient preferences are very valuable, there is little guidance on conducting and using such studies. The goal of PREFER will be to provide a set of systematic methodologies and recommendations to assess, engage and include patient perspectives during the development, approval, and post-approval of new therapies. PREFER brings together experts from academic research institutions, pharmaceutical companies, patient organisations, a health technology assessment body, and small and medium-sized enterprises. In addition the consortium has set up stakeholder advisory groups to work closely with patients, regulators, health technology assessment (HTA) bodies and payers, to ensure that recommendations are evidence based, relevant and useful.

Achievements & News

IMI projects cited in new orphan drug development guidebook
September 2020

Three IMI projects – c4c, EUPATI and PREFER – are cited in a new Orphan Drug Development Guidebook released by the International Rare Diseases Research Consortium (IRDiRC). ###Developing ‘orphan drugs’ (i.e. drugs for rare diseases) is highly challenging, and just 5 % of rare diseases have an approved treatment. The IRDiRC describes the new guidebook as ‘a patient focused guidebook that describes the available tools, incentives, resources and practices for developing traditional and innovative drugs/therapies for rare diseases and how to best use them.’ It lists a range of resources from organisations around the world, including IMI.

c4c aims to generate a sustainable infrastructure that optimises the delivery of clinical trials in children, and the guidebook suggests this could be useful for those developing medicines for rare paediatric diseases.

On EUPATI, the guidebook describes its patient education resources as ‘very relevant to rare disease medicines development and highly useful and appreciated by the rare disease patients that finished the academy and use the toolbox’.

On PREFER, the guide highlights how patient preference studies can be useful during regulatory benefit-risk assessment for certain drugs in several major ways.

The guidebook is presented in an article in Nature Reviews Drug Discovery. ‘By enhancing the use of available tools, delays in development timelines can be avoided, risks and costs reduced, and patient and regulatory acceptability improved,’ the authors conclude.

Find out more

PREFER sets out 15 ways to listen to the patient voice
September 2020

There is now broad recognition that patients can and should be involved in all stages of medical research and drug development, as understanding patients’ preferences can improve decision-making. However, putting ‘patient-centricity’ into practice is not always easy. IMI’s PREFER project has now identified 15 critical decision points in industry, regulatory and health technology assessment (HTA) decision-making where input on patient preferences can support the process.###

Their findings are published in the journal Health Policy. ‘Currently, PP [patient preference] information is not considered as obligatory information to submit for any of the MPLC [medical product lifecycle] decision-points,’ the scientists write. ‘However, PP information is considered an important component by most stakeholders to inform future decision-making across the MPLC. The integration of PP information into 15 identified decision-points needs continued discussion and collaboration between stakeholders.’

First author Chiara Whichello of Erasmus University Rotterdam says: ‘We do see regulators and HTA having to take more steps to integrate patient preference information into their decision-making processes, compared to industry. Simply because they have to also take into account how much weight should be given to patients’ preferences compared to other required information, such as safety and cost-effectiveness.’

Find out more

IMI patient engagement projects sign memorandum of understanding
November 2018

Two IMI projects focusing on patient engagement, PARADIGM and PREFER, have signed a memorandum of understanding (MoU) to enhance collaboration between the projects and to maximise results. The MoU outlines how the projects will work together and share ideas. ###While PARADIGM is broadly focused on patient engagement at three points in the research and development process, PREFER looks at how and when it is best to perform and include patient preferences in decision making during the medical product life cycle. Through the MoU, the two projects hope to identify areas of mutual interest; identify any gaps that are hindering progress; establish collaborative activities to address these gaps; and share knowledge and data. The projects will also mutually participate in project events and use each other’s communications channels to promote news and results. In a joint statement, the projects write: ‘There is an ample opportunity to leverage the work of these projects, to avoid duplicate efforts as well as maximise results.’

Participants Show participants on map

EFPIA companies
  • AbbVie Ltd, Maidenhead, United Kingdom
  • Actelion Pharmaceuticals LTD, Allschwil, Switzerland
  • Amgen Limited, Cambridge, United Kingdom
  • Astellas Pharma Europe BV, Leiden, Netherlands
  • Astrazeneca AB, Södertälje, Sweden
  • Bayer Pharma AG, Berlin, Germany
  • Csl Behring GMBH, Marburg, Germany
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany
  • Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States
  • Novartis Pharma AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
  • Takeda Development Centre Europe LTD, London, United Kingdom
Universities, research organisations, public bodies, non-profit groups
  • Centre Federal D'Expertise Des Soins De Sante, Brussels, Belgium
  • Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
  • Erasmus Universiteit Rotterdam, Rotterdam, Netherlands
  • Forum Des Patients Europeens, 1040, Belgium
  • Instituto Tumori "Giovanni Paolo Ii", Bari, Italy
  • Katholieke Universiteit Leuven, Leuven, Belgium
  • The University Of Birmingham, Birmingham, United Kingdom
  • Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
  • Universitatsklinikum Erlangen, Erlangen, Germany
  • University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom
  • Uppsala Universitet, Uppsala, Sweden
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Istituto Europeo Di Oncologia SRL, Milan, Italy
  • Mindbytes, Merksplas, Belgium
  • Steinbeisser Project Management Ug (Haftungsbeschrankt), Munich, Germany
Patient organisations
  • European Cancer Patient Coalition, Brussels, Belgium
  • European Patients’ Forum (EPF), Brussels, Belgium
  • International Alliance Of Patient'Organizations, London, United Kingdom
  • Muscular Dystrophy Group Of Great Britain And Northern Ireland, London, United Kingdom
Project leader
Conny Berlin
Novartis Pharma AG
General questions
Contact[At]Imi-Prefer.Eu
Press contact and web related issues
Communications[At]Imi-Prefer.Eu